Insulin-like growth factor ternary complex components as biomarkers for the diagnosis of short stature

in European Journal of Endocrinology
View More View Less
  • 1 Division of Endocrinology, Department of Pediatrics, Medical School, University of Patras, Patras, Greece

Correspondence should be addressed to A Giannakopoulos Email agianak@gmail.com
Restricted access

Objective

The diagnosis of growth hormone deficiency (GHD) in children is not always straightforward because insulin-like growth factor 1 (IGF-I) or GH stimulation tests may not be able to discriminate GHD from constitutional delay of growth and puberty (CDGP) or other causes of short stature.

Design

Boys and girls (n = 429, 0.7–16 years) who attended our department for short stature participated in this study. They were followed up for an average period of 9 years. At the end of follow-up after reaching the final height, a definitive diagnosis was assigned, and all the components of ternary complex (IGF-I, IGF-binding protein-3 (IGFBP-3), acid-labile subunit (ALS), and IGF-I/IGFBP-3 ratio) were evaluated as biomarkers for the respective diagnosis.

Results

All the components of the ternary complex were tightly correlated with each other and were positively related to age. IGF-I, IGFBP-3, ALS, and IGF-I/IGFBP-3 ratio differed significantly between GHD and normal groups. IGF-I and ALS levels were lower in GHD compared to children with familial short stature, while IGF-I and IGF-I/IGFBP-3 ratio was significantly lower in GHD compared to children with CDGP. IGF-I and IGF-I/IGFBP-3 receiver operating curve cutoff points were unable to discriminate between GHD and normal groups or between GHD and CDGP groups.

Conclusion

Despite the tight correlation among all the components of the ternary complex, each one shows a statistically significant diagnosis-dependent alteration. There is a superiority of IGF-I, ALS, and IGF-I/IGFBP-3 ratio in the distinction between GHD and CDGP or between GHD and normal groups but without usable discriminating power, making auxology as the primary criterion for establishing the diagnosis.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 1049 1049 169
Full Text Views 47 47 1
PDF Downloads 76 76 5
  • 1

    Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Archives of Disease in Childhood 2016 101 96100. (https://doi.org/10.1136/archdischild-2014-307228)

    • Search Google Scholar
    • Export Citation
  • 2

    Sävendahl L, Cooke R, Tidblad A, Beckers D, Butler G, Cianfarani S, Clayton P, Coste J, Hokken-Koelega ACS & Kiess W et al.Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. Lancet: Diabetes and Endocrinology 2020 8 683692. (https://doi.org/10.1016/S2213-8587(2030163-7)

    • Search Google Scholar
    • Export Citation
  • 3

    Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH & Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Hormone Research in Paediatrics 2016 86 361397. (https://doi.org/10.1159/000452150)

    • Search Google Scholar
    • Export Citation
  • 4

    Voss LD, Wilkin TJ, Bailey BJ, Betts PR. The reliability of height and height velocity in the assessment of growth (the Wessex Growth Study). Archives of Disease in Childhood 1991 66 833837. (https://doi.org/10.1136/adc.66.7.833)

    • Search Google Scholar
    • Export Citation
  • 5

    Tauber M, Moulin P, Pienkowski C, Jouret B, Rochiccioli P. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 352356. (https://doi.org/10.1210/jcem.82.2.3726)

    • Search Google Scholar
    • Export Citation
  • 6

    Shalet SM, Toogood A, Rahim A, Brennan BMD. The diagnosis of growth hormone deficiency in children and adults. Endocrine Reviews 1998 19 203223. (https://doi.org/10.1210/edrv.19.2.0329)

    • Search Google Scholar
    • Export Citation
  • 7

    Juul A, Skakkebaek NE. Prediction of the outcome of growth hormone provocative testing in short children by measurement of serum levels of insulin-like growth factor I and insulin-like growth factor binding protein 3. Journal of Pediatrics 1997 130 197204. (https://doi.org/10.1016/s0022-3476(9770343-3)

    • Search Google Scholar
    • Export Citation
  • 8

    Clayton P, Bonnemaire M, Dutailly P, Maisonobe P, Naudin L, Pham E, Zhang Z, Grupe A, Thiagalingam A & Denèfle P et al.Characterizing short stature by insulin-like growth factor axis status and genetic associations: results from the prospective, cross-sectional, epidemiogenetic EPIGROW study. Journal of Clinical Endocrinology and Metabolism 2013 98 E1122E1130. (https://doi.org/10.1210/jc.2012-4283)

    • Search Google Scholar
    • Export Citation
  • 9

    Leong SR, Baxter RC, Camerato T, Dai J, Wood WI. Structure and functional expression of the acid-labile subunit of the insulin-like growth factor-binding protein complex. Molecular Endocrinology 1992 6 870876. (https://doi.org/10.1210/mend.6.6.1379671)

    • Search Google Scholar
    • Export Citation
  • 10

    Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man: estimations of half-lives and production rates. Acta Endocrinologica 1989 121 753758. (https://doi.org/10.1530/acta.0.1210753)

    • Search Google Scholar
    • Export Citation
  • 11

    Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. Journal of Endocrinology 2001 170 6370. (https://doi.org/10.1677/joe.0.1700063)

    • Search Google Scholar
    • Export Citation
  • 12

    Mandel SH, Moreland E, Rosenfeld RG, Gargosky SE. The effect of GH therapy on the immunoreactive forms and distribution of IGFBP-3, IGF-I, the acid-labile subunit, and growth rate in GH-deficient children. Endocrine 1997 7 351360. (https://doi.org/10.1007/BF02801330)

    • Search Google Scholar
    • Export Citation
  • 13

    Ertl DA, Chen J, Gleiss A, Janu D, Sagmeister S, Raimann A, Riedl S, Haeusler G. Diagnostic value of serum acid-labile subunit alone and in combination with IGF-I and IGFBP-3 in the diagnosis of growth hormone deficiency. Hormone Research in Paediatrics 2020 93 371379. (https://doi.org/10.1159/000512336)

    • Search Google Scholar
    • Export Citation
  • 14

    Ranke MB, Traunecker R, Martin DD, Schweizer R, Schwarze CP, Wollmann HA, Binder G. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age. Hormone Research 2005 64 6876. (https://doi.org/10.1159/000087692)

    • Search Google Scholar
    • Export Citation
  • 15

    Cabrol S, Perin L, Colle M, Coutant R, Jésuran-Perelroizen M, Le Bouc Y, Czernichow P. Evolution of IGF-1 in children born small for gestational age and with growth retardation, treated by growth hormone adapted to IGF-1 levels after 1 year. Hormone Research in Paediatrics 2011 76 419427. (https://doi.org/10.1159/000334651)

    • Search Google Scholar
    • Export Citation
  • 16

    Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. Journal of Clinical Endocrinology and Metabolism 2000 85 39903993. (https://doi.org/10.1210/jcem.85.11.6984)

    • Search Google Scholar
    • Export Citation
  • 17

    Ranke MB, Lindberg A & KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. Journal of Clinical Endocrinology and Metabolism 2010 95 12291237. (https://doi.org/10.1210/jc.2009-1471)

    • Search Google Scholar
    • Export Citation
  • 18

    Tillmann P, Gill W, Price K & Wales C Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clinical Endocrinology 2001 53 329336. (https://doi.org/10.1046/j.1365-2265.2000.01105.x)

    • Search Google Scholar
    • Export Citation
  • 19

    Wit JM, van Duyvenvoorde HA, Scheltinga SA, Bruin S, Hafkenscheid L, Kant SG, Ruivenkamp CA, Gijsbers AC, van Doorn J & Feigerlova E et al.Genetic analysis of short children with apparent growth hormone insensitivity. Hormone Research in Paediatrics 2012 77 320333. (https://doi.org/10.1159/000338462)

    • Search Google Scholar
    • Export Citation
  • 20

    Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van Doorn J, Juul A. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. Journal of Clinical Laboratory Analysis 1999 13 166172. (https://doi.org/10.1002/(SICI)1098-2825(1999)13:4<166::AID-JCLA5>3.0.CO;2-X)

    • Search Google Scholar
    • Export Citation
  • 21

    Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, Körner A, Obermayer-Pietsch B, Hübener C & Dahlgren J et al.Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. Journal of Clinical Endocrinology and Metabolism 2014 99 17121721. (https://doi.org/10.1210/jc.2013-3059)

    • Search Google Scholar
    • Export Citation
  • 22

    Friedrich N, Wolthers OD, Arafat AM, Emeny RT, Spranger J, Roswall J, Kratzsch J, Grabe HJ, Hübener C & Pfeiffer AFH et al.Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (igfbp-3) and the igf-i to igfbp-3 ratio measured by new automated chemiluminescence assays. Journal of Clinical Endocrinology and Metabolism 2014 99 16751686. (https://doi.org/10.1210/jc.2013-3060)

    • Search Google Scholar
    • Export Citation
  • 23

    Juul A, Møller S, Mosfeldt-Laursen E, Højby Rasmussen MH, Scheike T, Pedersen SA, Kastrup KW, Yu H, Mistry J & Rasmussen S et al.The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 44084415. (https://doi.org/10.1210/jcem.83.12.5311)

    • Search Google Scholar
    • Export Citation
  • 24

    Clayton P CUTPT: Stata Module for Empirical Estimation of Cutpoint for a Diagnostic Test. Boston College Department of Economics, 2013.

  • 25

    Boquete HR, Sobrado PGV, Fideleff HL, Sequera AM, Giaccio AV, Suárez MG, Ruibal GF, Miras M. Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. Journal of Clinical Endocrinology and Metabolism 2003 88 47024708. (https://doi.org/10.1210/jc.2003-030412)

    • Search Google Scholar
    • Export Citation
  • 26

    Cianfarani S, Liguori A, Boemi S, Maghnie M, Iughetti L, Wasniewska M, Street ME, Zucchini S, Aimaretti G, Germani D. Inaccuracy of insulin-like growth factor (IGF) binding protein (IGFBP)-3 assessment in the diagnosis of growth hormone (GH) deficiency from childhood to young adulthood: association to low GH dependency of IGF-II and presence of circulating IGFBP-3 18-kilodalton fragment. Journal of Clinical Endocrinology and Metabolism 2005 90 60286034. (https://doi.org/10.1210/jc.2005-0721)

    • Search Google Scholar
    • Export Citation
  • 27

    Löfqvist C, Andersson E, Gelander L, Rosberg S, Hulthen L, Blum WF, Wikland KA. Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. Journal of Clinical Endocrinology and Metabolism 2005 90 14201427. (https://doi.org/10.1210/jc.2004-0812)

    • Search Google Scholar
    • Export Citation
  • 28

    Galluzzi F, Quaranta MR, Salti R, Saieva C, Nanni L, Seminara S. Are IGF-I and IGF-BP3 useful for diagnosing growth hormone deficiency in children of short stature? Journal of Pediatric Endocrinology and Metabolism 2010 23 12731279. (https://doi.org/10.1515/jpem.2010.201)

    • Search Google Scholar
    • Export Citation
  • 29

    Luna AM, Wilson DM, Wibbelsman CJ, Brown RC, Nagashima RJ, Hintz RL, Rosenfeld RG. Somatomedins in adolescence: a cross-sectional study of the effect of puberty on plasma insulin-like growth factor I and II levels. Journal of Clinical Endocrinology and Metabolism 1983 57 268271. (https://doi.org/10.1210/jcem-57-2-268)

    • Search Google Scholar
    • Export Citation
  • 30

    Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. Journal of Clinical Endocrinology and Metabolism 1990 70 12921298. (https://doi.org/10.1210/jcem-70-5-1292)

    • Search Google Scholar
    • Export Citation
  • 31

    Hasegawa Y,, Hasegawa T, Aso T, Kotoh S, Nose O, Ohyama Y, Araki K, Tanaka T, Saisyo S & Yokoya S et al.Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency. European Journal of Endocrinology 1994 131 2732. (https://doi.org/10.1530/eje.0.1310027)

    • Search Google Scholar
    • Export Citation
  • 32

    Boer de H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, Veen van der E. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. Journal of Clinical Endocrinology and Metabolism 1996 81 13711377. (https://doi.org/10.1210/jcem.81.4.8636336)

    • Search Google Scholar
    • Export Citation
  • 33

    Barrios V, Argente J, Munoz MT, Pozo J, Chowen JA, Hernandez M. Diagnostic interest of acid-labile subunit measurement in relationship to other components of the IGF system in pediatric patients with growth or eating disorders. European Journal of Endocrinology 2001 144 245250. (https://doi.org/10.1530/eje.0.1440245)

    • Search Google Scholar
    • Export Citation
  • 34

    Frystyk J Free insulin-like growth factors: measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Hormone and IGF Research 2004 14 337375. (https://doi.org/10.1016/j.ghir.2004.06.001)

    • Search Google Scholar
    • Export Citation
  • 35

    Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jørgensen K, Müller J, Hall K, Skakkebaek NE. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. Journal of Clinical Endocrinology and Metabolism 1994 78 744752. (https://doi.org/10.1210/jcem.78.3.8126152)

    • Search Google Scholar
    • Export Citation
  • 36

    Juul A, Kastrup KW, Pedersen SA, Skakkebaek NE. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3. Journal of Clinical Endocrinology and Metabolism 1997 82 11951201. (https://doi.org/10.1210/jcem.82.4.3892)

    • Search Google Scholar
    • Export Citation